Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Social Justice Institute’s Rhonda Y. Williams discusses how protesters confront marginalization
- Psychological Sciences’ Lisa Damour writes about benefits of gap year before college
- International graduate/professional students: Register for Spoken English Seminar by May 8
- Reduce stress at upcoming meditation classes
- Next implicit bias session to focus on race